Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

A9950

Sigma-Aldrich

Aniracetam

≥98%

Synonym(s):

1-(4-Methoxybenzoyl)-2-pyrrolidinone, Ro 13-5057

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C12H13NO3
CAS Number:
Molecular Weight:
219.24
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

assay

≥98%

originator

Roche

SMILES string

COc1ccc(cc1)C(=O)N2CCCC2=O

InChI

1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3

InChI key

ZXNRTKGTQJPIJK-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Aniracetam has been used in the inhibition screening assays for kinase enzyme.

Biochem/physiol Actions

Aniracetam is a piracetam analog and has low bioavailability due to rapid excretion. It enhances the cognitive thinking and is effective for treatment of sleep and behavioral disorders. Aniracetam is prescribed for anxiety and also enhances learning and memory in situations with induced damage of the brain.
Cognition enhancer (nootropic) that potentiates AMPA receptor mediated ion conductance and potentiates metabotropic glutamate receptor activity.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chrysi C Koliaki et al.
CNS neuroscience & therapeutics, 18(4), 302-312 (2011-11-11)
Dementia constitutes an increasingly prevalent cognitive disorder with serious socioeconomic implications. In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a
A Pittaluga et al.
Naunyn-Schmiedeberg's archives of pharmacology, 359(4), 272-279 (1999-05-27)
Aniracetam, 1-(1,3-benzodioxol-5-yl-carbonyl)piperidine (1-BCP) and cyclothiazide, three compounds considered to enhance cognition through modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, were evaluated in the 'kynurenate test', a biochemical assay in which some nootropics have been shown to prevent the antagonism by kynurenic
Julia Vaglenova et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 33(5), 1071-1083 (2007-07-05)
Specific pharmacological treatments are currently not available to address problems resulting from fetal ethanol exposure, described as Fetal Alcohol Syndrome or Fetal Alcohol Spectrum Disorders (FASD). The present study evaluated the therapeutic effects of aniracetam against cognitive deficits in a
Kazuo Nakamura
CNS drug reviews, 8(1), 70-89 (2002-06-19)
Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease. New discoveries in the behavioral pharmacology, biochemistry and pharmacokinetics of aniracetam provided new
Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition.
Tomilov A, et al.
Pharmacological Research, 137(8), 89-103 (2018)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service